Gaxos.AI Inc Dossier - Source-backed chat

Gaxos.AI Inc

GXAINASDAQ

SectorConsumer Discretionary

IndustryInteractive Home Entertainment

Beta (adjusted)0.97

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.53Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $7.3M

Enterprise Value $6.2M

Shares Outstanding 13.8M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Gaxos.ai Inc. (NASDAQ: GXAI) is transitioning from a pre-revenue development stage to early commercialization, as evidenced by its Q1 2026 financial results. The company reported a significant revenue increase to $1.81 million, primarily driven by administrative services from RNK Health and subscription revenue from its AI applications (Art-Gen.ai, UnGPT.ai, and Bible Pray AI). However, this growth has been accompanied by widening net losses ($2.47 million in Q1 2026) due to aggressive advertising and marketing expenditures. While strategic moves—such as acquiring a 19.99% stake in America First Defense and securing additional development funding from Amazon Web Services (AWS)—provide exposure to high-growth sectors like defense tech and enterprise AI, the business remains highly speculative with a high cash burn rate. A 'Hold' recommendation is advised until the company demonstrates a sustainable path to profitability and successful commercial scaling of its proprietary AI platforms.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.70

Mean target$2.70

High · most bullish analyst$2.70

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.9120%

The bear case is triggered if consumer interest in Gaxos' current AI applications fades, or if the company fails to convert its marketing spend and pilot programs into sustainable, high-margin enterprise revenue. Rapid cash burn would deplete its working capital within the next 12 to 18 months, forcing aggressive equity dilution or debt issuance under unfavorable terms. Furthermore, any failure of its portfolio investments (like AFD) to gain commercial traction would severely impact valuation.

Base CaseCentral scenario

$2.7055%

Matches the consensus mean

The base case assumes Gaxos.ai continues to grow its early-stage revenue streams from RNK Health and consumer AI subscriptions, but at the cost of high operating expenses. Marketing and R&D costs will likely remain elevated, keeping the company in a net loss position for the near term. The company will rely on its existing working capital ($11.59 million as of March 31, 2026) and its at-the-market (ATM) equity program to fund operations, resulting in gradual dilution for existing shareholders.

Bull CaseUpside scenario

$2.7025%

The bull case relies on rapid commercial adoption of Gaxos Labs' AI applications and the successful launch of its AWS-backed enterprise sales coaching platform. Additionally, its 19.99% stake in America First Defense (AFD) could yield significant strategic value as AFD deploys Anduril's Lattice platform in the counter-drone defense market. Under this scenario, high-margin subscription and enterprise software revenues would scale rapidly, offsetting marketing expenses and driving the company toward profitability.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Significant revenue acceleration in Q1 2026 ($1.81M vs. $23.7K in Q1 2025), showing early signs of commercial traction.
Strategic diversification into defense technology through a 19.99% stake in America First Defense, capturing counter-drone market tailwinds.
Validation and financial support from Amazon Web Services (AWS) to accelerate Gaxos Labs' AI-powered sales coaching platform.
Solid short-term liquidity with $11.59M in working capital as of March 31, 2026, providing runway for product development.

Key Investment Risks

Widening net losses ($2.47M in Q1 2026) driven by high advertising and marketing expenses ($2.77M).
High dependence on a single customer/partner segment, with $1.25M of Q1 2026 revenue derived from RNK Health administrative services.
Potential for ongoing equity dilution through the company's at-the-market (ATM) equity program to fund operations.
Highly competitive and rapidly evolving generative AI and defense technology landscapes.

Thesis Invalidation Triggers

A material decline in quarterly subscription revenues from Gaxos Labs' AI applications.
Failure to secure commercial enterprise clients for the AWS-backed sales coaching platform by late 2026.
Depletion of working capital to under $3 million without a clear path to operating cash flow break-even.
Regulatory hurdles or deployment failures affecting America First Defense's counter-drone systems.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.